QC
CGEM icon

Quadrature Capital’s Cullinan Oncology CGEM Stock Holding History

Quadrature Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,577
Closed -$150K – 1643
2026
Q1 		$150K Buy
+10,577
New +$136K ﹤0.01% 1170
2025
Q4 		– Sell
-13,942
Closed -$82.7K – 1296
2025
Q3 		$82.7K Buy
+13,942
New +$102K ﹤0.01% 900

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Quadrature Capital's CGEM Position: Q2 2026 in Review

Quadrature Capital sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 10,577 shares — an estimated $150K sold.

Quadrature Capital first reported a position in CGEM in Q3 2025 and held it in 2 quarters. The position peaked at $150K in Q1 2026. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Quadrature Capital reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 10,577 Cullinan Oncology shares in Q2 2026, an estimated $150K.
  • Quadrature Capital first reported a position in Cullinan Oncology in Q3 2025 and held it in 2 quarters.
  • Quadrature Capital's Cullinan Oncology position peaked at $150K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.